PMID- 33166416
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20210714
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 61
IP  - 3
DP  - 2021 Mar
TI  - Minor impact of patient alloantibodies against human platelet antigen (HPA)-15 in 
      the effectiveness of platelet transfusion: A pilot study.
PG  - 738-743
LID - 10.1111/trf.16181 [doi]
AB  - BACKGROUND: Alloantibodies against human platelet antigen (HPA)-15 are sometimes 
      detected in patients with platelet transfusion refractoriness (PTR); however, 
      little is known about their impact on PTR. STUDY DESIGN AND METHODS: Two patients 
      who possessed HPA-15 alloantibodies (Patient 1, anti-HPA-15b; Patient 2, 
      anti-HPA-15a) and human leukocyte antigen (HLA) antibodies were enrolled. The 
      efficacy of HPA-15-compatible vs -incompatible platelet transfusion was compared 
      by focusing on ABO- and HLA-matched transfusions on the basis of the 24-hour 
      corrected count increment (CCI-24 hours) for platelets. The titers of HPA-15 
      antibodies in the patients' sera were also monitored. RESULTS: The patients 
      received 71 and 12 ABO-compatible, HLA-matched platelet transfusions, 
      respectively, during the monitoring periods. Among these transfusions, 
      CCI-24 hours could be calculated in 27 and 10 transfusions, respectively, and the 
      HPA-15 genotype of the donors was determined. There were no significant 
      differences in the CCI-24 hours between the HPA-15 compatible and incompatible 
      transfusions in both patients (P = .30 and .56, respectively, Mann-Whitney U 
      test). There was no significant change in the HPA-15b antibody titer in Patient 1 
      during the monitoring period, while the HPA-15a antibody level in Patient 2 was 
      undetectable at the end of the monitoring period, although the titer was low at 
      the beginning. CONCLUSION: The efficacy of HPA-15-incompatible platelet 
      transfusions was not necessarily inferior to that of HPA-15 compatible ones. 
      Although the case number was limited, our results suggest that HPA-15 antibodies 
      do not have a significant impact on the effects of platelet transfusion.
CI  - (c) 2020 AABB.
FAU - Inoue, Hiroko
AU  - Inoue H
AD  - Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.
FAU - Sakamoto, Rumi
AU  - Sakamoto R
AD  - Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.
FAU - Nishimiya, Hiroko
AU  - Nishimiya H
AD  - Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.
FAU - Sakamoto, Hiroe
AU  - Sakamoto H
AD  - Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.
FAU - Terasu, Shota
AU  - Terasu S
AD  - Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.
FAU - Aminaka, Ryota
AU  - Aminaka R
AD  - Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.
FAU - Koh, Yangsook
AU  - Koh Y
AD  - Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.
FAU - Takihara, Yoshihiro
AU  - Takihara Y
AD  - Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.
FAU - Hirayama, Fumiya
AU  - Hirayama F
AUID- ORCID: 0000-0001-6518-2085
AD  - Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.
FAU - Kuroishi, Ayumu
AU  - Kuroishi A
AUID- ORCID: 0000-0002-5940-0071
AD  - Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20201109
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Human Platelet)
RN  - 0 (CD109 protein, human)
RN  - 0 (GPI-Linked Proteins)
RN  - 0 (Isoantibodies)
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Aged
MH  - Antigens, CD/blood/*immunology
MH  - Antigens, Human Platelet/*immunology
MH  - Blood Group Incompatibility
MH  - Female
MH  - GPI-Linked Proteins/blood/immunology
MH  - Humans
MH  - Isoantibodies/*blood/immunology
MH  - Japan
MH  - Leukemia, Myeloid, Acute/blood/*immunology
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/blood/*immunology
MH  - Neoplasm Proteins/blood/*immunology
MH  - Pilot Projects
MH  - *Platelet Transfusion/adverse effects
MH  - Statistics, Nonparametric
OTO - NOTNLM
OT  - human platelet antigen-15
OT  - platelet transfusion
OT  - refractoriness
EDAT- 2020/11/10 06:00
MHDA- 2021/07/15 06:00
CRDT- 2020/11/09 17:13
PHST- 2020/10/12 00:00 [revised]
PHST- 2020/08/15 00:00 [received]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
PHST- 2020/11/09 17:13 [entrez]
AID - 10.1111/trf.16181 [doi]
PST - ppublish
SO  - Transfusion. 2021 Mar;61(3):738-743. doi: 10.1111/trf.16181. Epub 2020 Nov 9.